Valuation: RVL Pharmaceuticals plc

Market Cap 334K 293K 272K 250K 473K 31.99M 482K 3.24M 1.27M 15.71M 1.26M 1.23M 54.25M P/E 2021
-1.12x
P/E 2022 -1.95x
Enterprise Value 13.28M 11.65M 10.79M 9.93M 18.78M 1.27B 19.14M 129M 50.43M 624M 49.87M 48.78M 2.16B EV / Sales 2021
5.55x
EV / Sales 2022 2.49x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
1 month 0
Extreme 0
0
Current year 0
Extreme 0
0
1 year 0
Extreme 0
0
3 years 0
Extreme 0
0.5
5 years 0
Extreme 0
4.38
10 years 0
Extreme 0
9.9
Manager TitleAgeSince
Chief Operating Officer 44 01/01/2016
Human Resources Officer - 01/01/2016
Date Insider Type Main position Quantity % Market Cap.
19/10/23
Altchem Ltd.
SellCompany 14,122,659 12.6767%
19/10/23
Altchem Ltd.
SellCompany 14,122,659 12.6767%
18/10/23
Altchem Ltd.
SellCompany 3,421,537 3.0712%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 111
+0.44%+2.51%+4.36%+10.27% 50.73B
-1.57%-3.18%+379.41%+593.37% 39.73B
-0.14%+0.77%+29.61%-5.50% 34.69B
+1.76%-1.78%+20.55%+53.38% 33.21B
-0.06%-4.63%+2.94%+31.65% 26.76B
-1.93%-1.01% - - 16.8B
-1.49%-6.18%+65.50%+120.53% 15.37B
+0.78%+0.20%+14.69%+17.08% 13.78B
-0.97%-2.83%+11.09%-33.29% 12.85B
Average -0.34%-0.88%+66.02%+98.44% 24.39B
Weighted average by Cap. -0.24%-0.38%+81.17%+124.10%

Financials

2021 2022
Net sales 17.5M 15.35M 14.22M 13.08M 24.74M 1.68B 25.22M 169M 66.46M 823M 65.72M 64.28M 2.84B 49.72M 43.61M 40.39M 37.16M 70.3M 4.76B 71.66M 481M 189M 2.34B 187M 183M 8.07B
Net income -64.92M -56.94M -52.74M -48.53M -91.78M -6.21B -93.57M -629M -247M -3.05B -244M -238M -10.54B -51.69M -45.34M -41.99M -38.64M -73.08M -4.95B -74.5M -500M -196M -2.43B -194M -190M -8.39B
Net Debt 7.2M 6.32M 5.85M 5.38M 10.18M 689M 10.38M 69.72M 27.35M 338M 27.04M 26.45M 1.17B 12.95M 11.35M 10.52M 9.68M 18.3M 1.24B 18.66M 125M 49.16M 608M 48.61M 47.55M 2.1B
Logo RVL Pharmaceuticals plc
RVL Pharmaceuticals plc is a pharmaceutical company focused on developing and commercializing eye care and medical aesthetics products. The Company is focused on developing and commercializing products for an underserved patient population in ocular medicine and medical aesthetics. It operates in one business segment which focuses on developing and commercializing pharmaceutical products. The Company is commercializing Upneeq for treating acquired blepharoptosis (low-lying eyelids) in adults and is developing Arbaclofen ER tablets for alleviating spasticity in multiple sclerosis patients. Their healthcare provider customers include optometrists, ophthalmologists, oculoplastic surgeons, facial plastic surgeons, dermatologists, and other qualified practitioners. The target patient population comprises adults with droopy or low-lying eyelids, primarily females. Its commercial operations are managed by wholly owned subsidiaries, RVL Pharmaceuticals, Inc., and RVL Pharmacy, LLC.
Employees
125
Date Price Change Volume
10/07/26 $0.000001 0.00% 5,000
  1. Stock Market
  2. Stocks
  3. RVLPQ Stock